138 related articles for article (PubMed ID: 34558360)
1. Effectiveness and safety of eribulin for human epidermal growth factor receptor 2 negative metastatic breast cancer in a real-world population.
Díaz-Acedo R; Artacho Criado S; Jiménez Galán R; Gutiérrez Pizarraya A; Galván Banqueri M; Rodríguez-de-la-Borbolla-Artacho M; Marcos Rodríguez JA; Márquez Saavedra E
J Oncol Pharm Pract; 2022 Oct; 28(7):1573-1582. PubMed ID: 34558360
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting.
Dranitsaris G; Gluck S; Faria C; Cox D; Rugo H
Clin Ther; 2015 Jan; 37(1):134-44. PubMed ID: 25433768
[TBL] [Abstract][Full Text] [Related]
3. Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine.
Pivot X; Im SA; Guo M; Marmé F
Breast Cancer; 2018 May; 25(3):370-374. PubMed ID: 29302858
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
McIntyre K; O'Shaughnessy J; Schwartzberg L; Glück S; Berrak E; Song JX; Cox D; Vahdat LT
Breast Cancer Res Treat; 2014 Jul; 146(2):321-8. PubMed ID: 24699910
[TBL] [Abstract][Full Text] [Related]
5. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.
Pivot X; Marmé F; Koenigsberg R; Guo M; Berrak E; Wolfer A
Ann Oncol; 2016 Aug; 27(8):1525-31. PubMed ID: 27177860
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.
Twelves C; Cortes J; Vahdat L; Olivo M; He Y; Kaufman PA; Awada A
Breast Cancer Res Treat; 2014 Dec; 148(3):553-61. PubMed ID: 25381136
[TBL] [Abstract][Full Text] [Related]
7. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A
Clin Breast Cancer; 2019 Apr; 19(2):105-112. PubMed ID: 30679100
[TBL] [Abstract][Full Text] [Related]
8. Phase II Study of Eribulin Mesylate Administered Biweekly in Patients With Human Epidermal Growth Factor Receptor-2-negative Metastatic Breast Cancer.
Smith J; Irwin A; Jensen L; Tedesco K; Misir S; Zhu W; Almonte A; He Y; Xie R; Olivo M; O'Shaughnessy J
Clin Breast Cancer; 2020 Apr; 20(2):160-167. PubMed ID: 31980406
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer.
Chabot I; Zhao Q; Su Y
Curr Med Res Opin; 2020 Dec; 36(12):2025-2036. PubMed ID: 33044090
[TBL] [Abstract][Full Text] [Related]
10. Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center.
Sirvén MB; Fernández-Ortega A; Stradella A; Morilla I; Falo C; Vázquez S; Castany R; Villanueva R; Recalde S; Pérez VN; Gil-Gil M; Pernas S
BMC Pharmacol Toxicol; 2019 Nov; 20(1):68. PubMed ID: 31753013
[TBL] [Abstract][Full Text] [Related]
11. Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.
Inoue K; Saito T; Okubo K; Kimizuka K; Yamada H; Sakurai T; Ishizuna K; Hata S; Kai T; Kurosumi M
Breast Cancer Res Treat; 2016 Jun; 157(2):295-305. PubMed ID: 27125669
[TBL] [Abstract][Full Text] [Related]
12. Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.
Yardley DA; Reeves J; Dees EC; Osborne C; Paul D; Ademuyiwa F; Soliman H; Guthrie T; Andersen J; Krekow L; Choksi J; Daniel B; Danso M; Favret A; Oommen S; Brufsky A; Bromund JL; Lin Y; Ibrahim AB; Richards PD
Clin Breast Cancer; 2016 Dec; 16(6):471-479.e1. PubMed ID: 27569274
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting.
Inoue K; Takahashi M; Mukai H; Yamanaka T; Egawa C; Sakata Y; Ikezawa H; Matsuoka T; Tsurutani J
Invest New Drugs; 2020 Oct; 38(5):1540-1549. PubMed ID: 31950374
[TBL] [Abstract][Full Text] [Related]
14. Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study.
Pedersini R; Vassalli L; Claps M; Tulla A; Rodella F; Grisanti S; Amoroso V; Roca E; Simoncini EL; Berruti A
Oncology; 2018; 94 Suppl 1(Suppl 1):10-15. PubMed ID: 30036867
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.
Cortes J; Hudgens S; Twelves C; Perez EA; Awada A; Yelle L; McCutcheon S; Kaufman PA; Forsythe A; Velikova G
Breast Cancer Res Treat; 2015 Dec; 154(3):509-20. PubMed ID: 26567010
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan.
Lin YJ; Kuo CN; Ko Y
Breast; 2021 Jun; 57():18-24. PubMed ID: 33706025
[TBL] [Abstract][Full Text] [Related]
17. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.
Kaufman PA; Awada A; Twelves C; Yelle L; Perez EA; Velikova G; Olivo MS; He Y; Dutcus CE; Cortes J
J Clin Oncol; 2015 Feb; 33(6):594-601. PubMed ID: 25605862
[TBL] [Abstract][Full Text] [Related]
18. Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.
Aftimos P; Polastro L; Ameye L; Jungels C; Vakili J; Paesmans M; van den Eerenbeemt J; Buttice A; Gombos A; de Valeriola D; Gil T; Piccart-Gebhart M; Awada A
Eur J Cancer; 2016 Jun; 60():117-24. PubMed ID: 27107326
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study.
Takamizawa S; Shimoi T; Satomi-Tsushita N; Yazaki S; Okuya T; Kojima Y; Sumiyoshi-Okuma H; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Yonemori K
BMC Cancer; 2022 Jan; 22(1):64. PubMed ID: 35027011
[TBL] [Abstract][Full Text] [Related]
20. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
Cortes J; O'Shaughnessy J; Loesch D; Blum JL; Vahdat LT; Petrakova K; Chollet P; Manikas A; Diéras V; Delozier T; Vladimirov V; Cardoso F; Koh H; Bougnoux P; Dutcus CE; Seegobin S; Mir D; Meneses N; Wanders J; Twelves C;
Lancet; 2011 Mar; 377(9769):914-23. PubMed ID: 21376385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
